Shots: The P-lll CAN-COVID trial involves assessing Ilaris (canakinumab) + SOC vs PBO + SoC in 454 patients aged 18-98yrs. with COVID-19 pneumonia and cytokine release syndrome CRS, with its expected full results in early 2021 Result: The trial fails to meet its 1EPs of survival without the need for mechanical ventilation up to day29 […]Read More
Shots: The P-II POC study assess safety and efficacy of ANG-3777 (2.0 mg/kg, IV) + SOC vs PBO + SOC in ~100 patients in a ratio (1:1) hospitalized with confirmed COVID-19 pneumonia with 1EPs as the proportion of patients alive, without the need for mechanical ventilation and renal replacement therapy (on an ongoing basis) @28day […]Read More
Shots: The P-III REMDACTA study involves assessing of Actemra + remdesivir vs PBO + remdesivir in hospitalized patients with severe COVID-19 pneumonia receiving SOC with 1EPs & 2EPs as clinical status, mortality, mechanical ventilation & ICU variables. The study is expected to initiate the enrollment with a target of ~450 globally, including the US, Canada […]Read More
Shots::stohthShots: Novartis to initiate P-III CAN-COVID study assessing the efficacy of canakinumab vs PBO on top of SOC in patients with COVID-19 pneumonia with its anticipated results in late summer 2020 The company plans to enroll 450 patients across France, Germany, Italy, Spain, UK and the US with an aim to evaluate canakinumab + SoC […]Read More
Shots: The P-III COVACTA study will evaluate the safety and efficacy of Actemra/RoActemra (tocilizumab) + SOC vs PBO + SOC in adult hospitalized patients with severe COVID-19 pneumonia The study is expected to be initiated in early Apr’2020 and will evaluate the therapy in ~300 patients globally, including the US with the 1EPs & 2EPs […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
